The Role of Drug Combination in Modern Medicine: Delta4’s Innovative Approach
The use of multiple active ingredients in medicine is a time-honored practice, with roots stretching back to Traditional Chinese Medicine (TCM) and various formulations in traditional medicine across the world based on the combination of plant and natural substances [24764197, 29799486, 36114271]. Combining multiple active ingredients, also known as drug combinations, is an increasingly important […]
Delta4: A Trusted Partner in EU Horizon Research Projects
Delta4 is proud to announce its participation in two significant EU Horizon research projects: PICKED (Personalized Medicine in Chronic Kidney Disease) and PROMOTE (Prostate Cancer Omics Mediated Intervention). Horizon Europe is the world’s largest research funding program, focusing on advancing health, biomedical research, data science, and AI/ML. With a total budget of nearly EUR 100 […]
Leveraging Multi-Omics Data for Drug Repurposing and Discovery at Delta4
At Delta4, we leverage multi-omics data to identify novel drug repurposing opportunities by uncovering molecular similarities between diseases and existing drugs. This integrative approach holds promise for accelerating the development of effective treatment strategies across rare and complex conditions. What is Omics Data? Omics data refers to comprehensive datasets that capture various types of molecular […]
Delta4 Featured in the Finanz und Wirtschaft (FuW)
Delta4 is honored to have been featured in a recent article by Finanz und Wirtschaft, highlighting our pioneering work in AI-driven drug repurposing. The article sheds light on how our AI-powered platform, Hyper-C, identifies novel therapeutic uses for existing drugs, offering hope for more efficient and effective treatment strategies for a range of complex conditions. […]
Biomedical Knowledge Graphs for Drug Discovery: Delta4’s Innovative Approach
The term “knowledge graph” describes the process of storing data in a graph-structured topology. A graph database consists of three main elements: nodes, edges, and properties. Nodes symbolize instances or entities, such as proteins, diseases, or tissues. Edges, otherwise known as relationships, provide a contextual connection between nodes. Properties, on the other hand, enrich both […]
The Path to New Therapies for Focal Segmental Glomerulosclerosis (FSGS)
Developing new treatments for complex diseases presents a myriad of challenges, ranging from understanding the disease’s mechanisms to ensuring the safety and effectiveness of proposed therapies. At Delta4, we’re passionately pursuing new treatments for Focal Segmental Glomerulosclerosis (FSGS). Leveraging our in-silico platform, Hyper-C, we’ve been able to identify new potential therapeutic options for FSGS. This […]
Pioneering the Future of Nephrotic Syndrome Research with ARREST-NEPHROSIS
Nephrotic Syndrome affects millions globally, presenting a significant health burden with its hallmark symptoms of severe proteinuria and edema. The quest for advanced treatments underscores the crucial role of biobanks and registries, which are instrumental in propelling medical research and innovation. At the forefront of this effort is ARREST-NEPHROSIS, an Austrian registry that exemplifies how […]
What to Expect From The Pharmaceutical Industry In 2024
As we step into 2024, the pharmaceutical industry stands at the cusp of remarkable advancements and significant transformations. This year promises to be a pivotal one, with key trends, innovations, and challenges shaping the future of healthcare and medicine and defining the pharmaceutical landscape. Key Pharmaceutical Industry Trends to Watch in 2024 Let’s explore the […]
Digital Health Envision Summit
We are delighted to announce that Dr. Klaus Kratochwill, CSO, and Dr. Paul Perco, Computational Biology Lead of Delta4, are looking forward to attending the prestigious 2023 Digital Health Envision Summit to be held in London, UK. The summit, renowned for being a hub of innovation in healthcare and neurology, aligns seamlessly with Delta4’s mission […]
Case Study: Unravelling the Multifaceted Potential of Iguratimod with Delta4’s Hyper-C Platform
Diving deep into the realms of computational drug repurposing, Delta4 leveraged its state-of-the-art Hyper-C platform with an ambitious objective: to comprehensively understand and broaden the applications of the anti-inflammatory compound iguratimod. At the heart of this project was the creation of a molecular Mechanism of Action (MoA) model. This intricate model was meticulously constructed around […]